FRANCE DIABETES DEVICES MARKET - GROWTH, TRENDS, COVID-19 IMPACT, AND FORECASTS (2022 - 2027)

FRANCE DIABETES DEVICES MARKET - GROWTH, TRENDS, COVID-19 IMPACT, AND FORECASTS (2022 - 2027)

The France Diabetes Devices Market is expected to register a CAGR greater than 7% over the forecast period, 2022-2027.

One of the most significant risk factors for a severe course of COVID-19 is diabetes mellitus. This risk is believed to be influenced by several variables that are frequently present in diabetes mellitus, such as advanced age, a proinflammatory and hypercoagulable condition, hyperglycemia, and underlying comorbidities (hypertension, cardiovascular disease, chronic kidney disease, and obesity). Diabetes was quickly recognized as a risk factor for bad results during the coronavirus disease-2019 (COVID-19) pandemic epidemic. Diabetes has previously been identified as a significant risk factor for death in individuals infected with either the Middle East respiratory syndrome-related coronavirus (MERS-CoV) or the 2009 H1N1 pandemic influenza. More recently, one of the main comorbidities linked to COVID-19 has consistently been diabetes.

Diabetes has the highest prevalence among all chronic conditions covered 100% by France's statutory health insurance (SHI), and the number of covered patients has doubled in the past 10 years. France is one of the major countries in the Europe region. According to the World Health Organization (WHO), about a million are diagnosed with diabetes in France. The prevalence of diabetes is growing among all ages in France, which can be attributed to the growing obese population, along with unhealthy diets and sedentary lifestyles of people. Furthermore, approximately 0.26 million are estimated to live with Type 1 diabetes in the region. Thus, the rising prevalence of diabetes and obesity, growing awareness, regarding diabetic care, healthcare expenditure, and technological advancements are a few factors that are further driving the market for diabetes care devices in France. In France, there is a centralized health care system their all the reimbursement decisions are taken at a national level and then applies to all of the countries. For diabetes technological devices in France, the reimbursement is based on the tariff system.

Key Market TrendsMonitoring Devices Hold Highest Market Share in France Diabetes Care Devices Market

In France, over a lifetime time horizon, the G6 RT-CGM system is likely to be cost-effective compared with SMBG for individuals with long-standing T1D. One of the commitments stipulated in the French National Health Strategy for 2018–2022 is to guarantee prompt and universal access to innovations such as new medical devices. However, there are increasing financial pressures within many health systems, meaning that the cost of innovative technologies should be justified by a sufficient clinical benefit to supersede currently available technologies. In view of the incremental clinical and QoL benefits afforded by the Dexcom G6 RT-CGM system in France. As people suffering from diabetes are at an increased risk of COVID-19 infection, the French companies are ensuring an adequate supply of required Monitoring Devices in the market to ensure the well-being of the affected citizens.

In France, the insurance plans reduce the burden on the diabetic population. However, different policies exist for both the Type 1 and Type 2 diabetic populations. For instance, the insurance covers up to 200-400 test strips in a year for the Type 2 population, whereas for the Type 1 population, it covers approximately 3,000 test strips in a year.

Increasing Diabetes Population in France Boosting the France Diabetes Devices Market during forecasting period 2022-2027..

In France, Type-1 Diabetes Population Increased with a CAGR greater than 3 % over the forecast period 2022-2027. France is one of the 59 nations in the IDF EUR area. Moreover, in 2021, 61 million individuals in the Europe Region and 537 million people worldwide have diabetes; by 2045, this number will increase to 69 million. According to a survey by the EU Commission, the number of persons in France who have chronic diabetes is the greatest, and one in 10 people in France are suffering from diabetes. The prevalence of diabetes is significant in France, although the rules' target of 80% compliance with advised healthcare consultations isn't always met. To promote proactive therapy adjustment and decrease therapeutic inertia, new techniques that focus on patient and physician education and information are necessary to lessen the burden of complications and hospitalizations associated with diabetes.

Therefore, owing to the aforesaid factors the growth of the studied market is anticipated in France Country.

Competitive Landscape

The new technologies in diabetes devices, like continuous glucose monitoring, increased the market for monitoring devices. The mergers and acquisitions between the players, like the acquisition of TypeZero Technologies by Dexcom, are paving the way for automated insulin delivery. The acquisition has sent Dexcom ahead on its way in the race to create an artificial pancreas system, rather than merely offering a boost to the continuous glucose monitoring devices market.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

Please note: This publisher does offer titles that are created upon receipt of order. If you are purchasing a PDF Email Delivery option above, the report will take approximately 2 business days to prepare and deliver.